Who to call at Salarius Pharmaceuticals, Inc., and when
Fundz watches for the moments Salarius Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day Salarius Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Salarius Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Salarius Pharmaceuticals, Inc.. With Fundz connected, it knows.
Salarius Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
salariuspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Salarius Pharmaceuticals' board approved a $225,000 cash transaction bonus for Acting CEO and CFO Mark J. Rosenblum, payable after the closing of the pending Decoy Therapeutics merger if he remains employed through closing. The bonus is a retention incentive tied to a merger agreement amended five times in 2025.
Key Takeaways
The board approved a $225,000 cash transaction bonus for Mark J. Rosenblum, who serves as Acting CEO, EVP and CFO.
Payment is conditioned on Rosenblum's continued employment through the closing date of the Decoy Therapeutics merger and will be paid at or before the next payroll date after closing.
3 more takeaways
Filing Overview
What This Means
Salarius Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.